@IntensityInc

Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to create safer and more efficacious cancer therapies. Nasdaq: $INTS

 Shelton, CT
intensitytherapeutics.com
Joined February 2013
  • Tweets755
  • Following258
  • Followers960
167Media
From a personal journey with breast cancer to the big screen. 🎬💗 This #BreastCancerAwarenessMonth, we’re proud to celebrate our collaborator and breast cancer survivor @handychristine1 as Hello Beautiful, inspired by her bestselling novel Walk Beside Me, arrives in theaters. We’re honored to stand beside Christine in helping bring greater awareness, education and hope to women facing breast cancer. Congratulations, Christine!
Lew Bender and former Victoria's Secret model and Breast Cancer Survivor Christine Handy stand in front of a scientific poster presentation at a conference. Both are holding certificates and smiling. They are on a carpeted floor in a large indoor venue with visible lighting fixtures above.

ALT Lew Bender and former Victoria's Secret model and Breast Cancer Survivor Christine Handy stand in front of a scientific poster presentation at a conference. Both are holding certificates and smiling. They are on a carpeted floor in a large indoor venue with visible lighting fixtures above.

1
1
15
258
This October, we’re thinking pink🎗💗 For #BreastCancerAwarenessMonth, we’re recognizing the patients, families, advocates & researchers driving progress while continuing our own work in TNBC through the Phase 2 INVINCIBLE-4 study. More to come! $INTS
Breast Cancer Awareness Month poster featuring a large pink ribbon design and the Intensity Therapeutics logo at the bottom.

ALT Breast Cancer Awareness Month poster featuring a large pink ribbon design and the Intensity Therapeutics logo at the bottom.

1
9
355
CEO Lewis H. Bender joins Jim Cornall on Base to Base Podcast to talk INT230-6, intratumoral treatment and Intensity’s approach to killing cancer cells while stimulating an immune response. 🎧 Intensity’s conversation starts around the 29-minute mark: deeptechdigest.com/biotech/b… $INTS
3
15
622
18 issued patents. 42 countries. 🌎 Our proprietary DfuseRx℠ technology is central to $INTS' approach to intratumoral cancer therapy and the development of INT230-6. Explore the science and IP behind our late-stage clinical programs: bit.ly/3T27pUh
The image features a promotional graphic from Intensity Therapeutics. It includes the phrases "Proprietary Science. Global Protection." and highlights "18 Issued Patents" and "42 Countries" on a green gradient background.

ALT The image features a promotional graphic from Intensity Therapeutics. It includes the phrases "Proprietary Science. Global Protection." and highlights "18 Issued Patents" and "42 Countries" on a green gradient background.

1
1
18
787
Our investigational INT230-6 is designed to kill tumors directly while stimulating a systemic anti-cancer immune response. With two late-stage clinical programs underway, we’re advancing a novel approach to treating solid tumors. Learn more about our technology and clinical programs: intensitytherapeutics.com @Nasdaq: $INTS
The image features the text "A New Weapon in the War on Cancer" in bold white letters on a green gradient background with stylized green lines. The logo of Intensity Therapeutics appears at the bottom right.

ALT The image features the text "A New Weapon in the War on Cancer" in bold white letters on a green gradient background with stylized green lines. The logo of Intensity Therapeutics appears at the bottom right.

1
2
1
13
654
$INTS CEO Lew Bender caught up with Dr. Swayampakula Ramakanth, Managing Director of Equity Research at @HCWCO, during this week's conference in NYC. Great connecting with the investment community!
Lew Bender from Intensity Therapeutics and an analyst from H.C. Wainwright together at their conference in NYC.

ALT Lew Bender from Intensity Therapeutics and an analyst from H.C. Wainwright together at their conference in NYC.

2
17
736
Going to @HCWCO? So is Lew. $INTS President & CEO Lewis H. Bender will be available for 1:1 meetings Sept. 14–16 in NYC. Come talk INT230-6, our late-stage clinical programs and what’s ahead for Intensity. 🤝 Request a meeting: bit.ly/3gk8b7C
The image is a promotional graphic for H.C. Wainwright featuring a person in business attire. The text announces that the Intensity Therapeutics President and CEO will attend for one-on-one meetings from September 14-16, 2026. The Intensity Therapeutics logo is in the top right corner.

ALT The image is a promotional graphic for H.C. Wainwright featuring a person in business attire. The text announces that the Intensity Therapeutics President and CEO will attend for one-on-one meetings from September 14-16, 2026. The Intensity Therapeutics logo is in the top right corner.

1
1
12
670
Treat locally. Act globally. Think differently about cancer. That idea has shaped $INTS since its founding and continues to drive the development of INT230-6: an investigational intratumoral therapy designed to kill tumors locally while engaging the immune system. Learn more about Intensity and our approach: bit.ly/4o9KWzf
2
11
689
$INTS is heading to New York. President & CEO Lewis H. Bender will participate in the @HCWCO Global Investment Conference Sept. 14–16. Watch the presentation: bit.ly/4AaYCjw Request a meeting: bit.ly/3gk8b7C Learn More: bit.ly/4ij34WP
Press release announcement for Intensity Therapeutics' participation in the H.C. Wainwright 28th Annual Global Investment Conference. The date mentioned is September 11, 2026, and availability on-demand at 7:00 am ET.

ALT Press release announcement for Intensity Therapeutics' participation in the H.C. Wainwright 28th Annual Global Investment Conference. The date mentioned is September 11, 2026, and availability on-demand at 7:00 am ET.

2
15
612
Big challenges call for great collaborators. $INTS has worked with @Merck, @bmsnews, and the @theNCI to explore INT230-6, including combinations with checkpoint inhibitors and research into its immune effects. Learn more: bit.ly/4n6awnX
The image features the logos of Merck, the National Cancer Institute (NIH), and Bristol Myers Squibb, under the heading "Our Partners: Advancing cancer research through collaboration." The Intensity Therapeutics logo is in the bottom right corner.

ALT The image features the logos of Merck, the National Cancer Institute (NIH), and Bristol Myers Squibb, under the heading "Our Partners: Advancing cancer research through collaboration." The Intensity Therapeutics logo is in the bottom right corner.

3
2
13
816
200+ patients of clinical experience. Two late-stage programs moving the pipeline forward. $INTS is advancing INT230-6 through Phase 3 in advanced soft tissue sarcoma and Phase 2 in neoadjuvant TNBC.
The image features the Intensity Therapeutics logo in the top right corner. Text in bold green reads "200+ Patients enrolled in 2 completed clinical trials, 2 Late-Stage Programs," and additional green text states "Phase 3 Sarcoma + Phase 2 TNBC." The background has wavy, abstract yellow lines.

ALT The image features the Intensity Therapeutics logo in the top right corner. Text in bold green reads "200+ Patients enrolled in 2 completed clinical trials, 2 Late-Stage Programs," and additional green text states "Phase 3 Sarcoma + Phase 2 TNBC." The background has wavy, abstract yellow lines.

3
15
646
What makes $INTS different starts with drug delivery. INT230-6 is designed to deliver potent anti-cancer agents directly into solid tumors, addressing a fundamental challenge in oncology as Intensity advances its late-stage clinical programs.
Intensity Therapeutics promotional image with a magnified cell visual. Text reads: "Solid Tumors: Why are these invaders so hard to treat?" Additional text explains challenges in treating cancers due to lack of blood vessels, dense composition, high fat content, and difficulty in drug delivery. Background is a gradient of blue and green.

ALT Intensity Therapeutics promotional image with a magnified cell visual. Text reads: "Solid Tumors: Why are these invaders so hard to treat?" Additional text explains challenges in treating cancers due to lack of blood vessels, dense composition, high fat content, and difficulty in drug delivery. Background is a gradient of blue and green.

1
14
619
#ICYMI: Lewis Bender joined Drug Delivery Leader to discuss how intratumoral therapy may help overcome some of the limitations of traditional systemic cancer treatments. Read more about the potential of this approach for patients with #solidtumors: bit.ly/4eQ0jKA $INTS

Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors

Intratumoral injection bypasses the tumor’s physical defenses entirely, killing cancer cells and creating a personalized immune response that destroys solid tumors.

drugdeliveryleader.com
2
14
584
Coordinating investigator @MarkusJoerger, MD, PhD Professor of Medicine at the University of Basel, shared his perspective on the potential of INT230-6 in the ongoing Phase 2 INVINCIBLE-4 study for patients with presurgical #TNBC. Read more: bit.ly/4w8l7TM $INTS
2
13
707
Progress looks different when you zoom in. Q2 brought financial and clinical momentum for $INTS, including encouraging preliminary INVINCIBLE-4 data, restarted patient treatment and the opening of our first site in France for accrual. See the highlights ↓ bit.ly/4caJxny
2
15
753
$INTS reported Q2 2026 financial results and a business update, including progress across our Phase 3 INVINCIBLE-3 sarcoma and Phase 2 INVINCIBLE-4 TNBC studies, plus increased business development activity. Read more: bit.ly/4caJxny
2
1
14
766
We've spent decades asking how to kill tumors. What if we should also be asking what happens next? 🎙️ Founder & CEO Lew Bender joined @KarenJagoda on the #EmpoweredPatientPodcast to discuss INT230-6, intratumoral therapy, and Intensity's investigational approach to causing cancer cell death in a new way that engages the immune system. 🎧 Listen here: bit.ly/4hS2JtP
Certainly! Here's the alt text: "Podcast cover image featuring a microphone illustration. Photos of Karen Jagoda, host of Empowered Patient Podcast, and Lew Bender, President & CEO at Intensity Therapeutics, Inc., are shown."

ALT Certainly! Here's the alt text: "Podcast cover image featuring a microphone illustration. Photos of Karen Jagoda, host of Empowered Patient Podcast, and Lew Bender, President & CEO at Intensity Therapeutics, Inc., are shown."

11
532
Mark your calendar. Join us on Tuesday, August 11 at 8:00 a.m. ET as Intensity Therapeutics reports second quarter 2026 financial results and shares a corporate update, including progress across our clinical development programs. Learn more here: bit.ly/4pT5I7k #IntensityTherapeutics #Oncology #CancerResearch #ClinicalTrials $INTS
2
2
16
691
$INTS' Phase 2 INVINCIBLE-4 study evaluating INT230-6 in presurgical #TNBC has recently resumed patient enrollment in Switzerland. Read @DDWJournal's coverage of the study restart: bit.ly/4yxFv1Y

Phase II triple-negative breast cancer trial restarts - Drug Discovery World (DDW)

Intensity Therapeutics has administered INT230-6 in the INVINCIBLE-4 Study in Switzerland.

ddw-online.com
2
17
953
Load more